Proventus Bioscience has launched LifeLore Pathways, a new independent biotech company based in Montreal.
While Proventus specialises in mature, large-scale projects, LifeLore operates upstream where promising concepts still require validation, formulation, and functional proof. Designed for speed and flexibility, the company is aiming to provide the scientific infrastructure needed to secure and accelerate early-stage biological innovation.
Microbial science is now central to innovation strategies in nutraceuticals, cosmetics, regenerative agriculture, and waste management. Thanks to advances in strain characterisation and stabilisation, applications like next-gen probiotics, pharmaceutical postbiotics, soil bioactivators, and functional food ingredients are rapidly moving from lab to market.
“We’re seeing a convergence between what technology enables and what the market demands,” said Vincent DeLorenzo, founder of Proventus Bioscience.
“Companies want to innovate faster, consumers demand natural and effective products, and regulators are steering the industry toward biological alternatives. LifeLore Pathways sits at this crossroads.”
LifeLore operates from a GMP-compliant lab facility designed to produce small-scale microbial batches for formulation, stability testing, and pilot trials. These early-stage lots support proof-of-concept, regulatory filings, and field validation without the need for immediate industrial scale-up.
The company offers flexible collaboration models: fee-for-service, co-development, or early-stage licensing, with clear deliverables and scientific oversight.
“When you’re working with living systems, two things matter most: scientific rigour and trust,” DeLorenzo said.
“LifeLore is built on both with strict IP protections and a team that understands both the science and the business.”
LifeLore focuses on accelerating the transition to sustainable medicines, enzymes, and alternative proteins by combining bioscience, automation, and quality systems making breakthrough bioprocesses as dependable as legacy chemistry.
Its primary application areas include: biologics and enzymes such as recombinant cytokines, diagnostic enzymes, vaccine antigens, and RNA polymerases; precision-fermented food proteins including casein, egg-white albumen, collagen peptides, and heme analogues; and industrial and specialty ferments like biopolymer precursors, bioremediation enzymes, and agricultural biologicals.
LifeLore is also preparing for expansion across Europe and Latin America, where demand for agile microbial development partners is rapidly accelerating.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.